Literature DB >> 20696816

Radiotherapy for glottic T1N0 carcinoma with slight hypofractionation and standard overall treatment time: importance of overall treatment time.

Rikiya Onimaru1, Masakazu Hasegawa, Kouichi Yasuda, Akihiro Homma, Nobuhiko Oridate, Satoshi Fukuda, Hiroki Shirato.   

Abstract

OBJECTIVE: We retrospectively investigated treatment outcomes in patients with glottic T1 carcinoma treated with 65 Gy in 26 fractions four times a week and discuss the importance of the overall treatment time.
METHODS: Two hundred one patients with glottic T1 carcinoma were evaluated. Sixty-five Gray in 26 fractions were delivered for 200 patients, whereas 1 patient received 62.5 Gy in 25 fractions. We delivered radiotherapy once daily four times a week in this period, for a weekly dose of 10 Gy. Weekdays except Wednesday were treatment days.
RESULTS: The overall survival rate was 96.8 ± 1.3% (standard error) at 3 years and 90.8 ± 2.2% at 5 years. The local control rate was 91.9 ± 2.0% at 3 years and 89.8 ± 2.3% at 5 years. In patients with an overall treatment time equal to or longer than 47 days, the local control rate was 82.6 ± 6.0% at both 3 and 5 years. In the patients with overall treatment time equal to or less than 46 days, the local control rate was 94.6 ± 1.9% at 3 years and 91.8 ± 2.4% at 5 years. There was a significant difference between these two groups (P = 0.0349). A severe late radiation reaction occurred in one patient. He experienced severe laryngeal edema that required tracheotomy at 6 months after the completion of radiotherapy. The tracheotomy was closed at 14 months after completion of radiotherapy.
CONCLUSIONS: Overall treatment time seems to be an important factor for a good local control rate for glottic T1N0 carcinoma even when treated with slight hypofractionation.

Entities:  

Mesh:

Year:  2010        PMID: 20696816     DOI: 10.1093/jjco/hyq153

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  6 in total

1.  Hypofractionated accelerated radiotherapy in T1-3 N0 cancer of the larynx: A prospective cohort study with historical controls.

Authors:  Zbigniew Szutkowski; Andrzej Kawecki; Andrzej Jarząbski; Zofia Laskus; Romuald Krajewski; Wojciech Michalski; Paweł Kukołowicz
Journal:  Rep Pract Oncol Radiother       Date:  2016-09-20

Review 2.  3D conformal hypofractionated radical radiotherapy in early glottic cancer.

Authors:  Ana Cristina Amado; Laurentiu Bujor; Isabel Monteiro Grillo
Journal:  Rep Pract Oncol Radiother       Date:  2013-05-30

3.  Outcomes of carotid-sparing IMRT for T1 glottic cancer: Comparison with conventional radiation.

Authors:  Abdallah S R Mohamed; Blaine D Smith; Joshua B Smith; Parag Sevak; Jessica S Malek; Aasheesh Kanwar; Theodora Browne; G Brandon Gunn; Adam S Garden; Steven J Frank; William H Morrison; Jack Phan; Mark Zafereo; Heath Skinner; Stephen Y Lai; Katherine A Hutcheson; Jan S Lewin; Amy E Hessel; Apurva A Thekdi; Randal S Weber; Clifton D Fuller; David I Rosenthal
Journal:  Laryngoscope       Date:  2019-02-12       Impact factor: 3.325

4.  Evaluation of acute/late toxicity and local recurrence in T1-T2 glottic carcinoma treated with accelerated hypofractionated 3D-conformal external beam radiotherapy (3D-CRT).

Authors:  Vassilis E Kouloulias; Anna Zygogianni; Eftychia Mosa; Kalliopi Platoni; John Georgakopoulos; Christos Antypas; Ivelina Beli; Maria Tolia; Paulos Maragoudakis; Ioannis Giotakis; Zisis Papas; Amanda Psyrri; Nikolaos Kelekis; John Kouvaris
Journal:  Radiol Oncol       Date:  2013-05-21       Impact factor: 2.991

5.  Hypofractionated radiotherapy for early glottic cancer: a retrospective interim analysis of a single institution.

Authors:  Jeong Won Lee; Jeong Eun Lee; Junhee Park; Jin Ho Sohn; Dongbin Ahn
Journal:  Radiat Oncol J       Date:  2019-06-30

6.  Short treatment time and excellent treatment outcome in accelerated hyperfractionated radiotherapy for T1 glottic cancer.

Authors:  Yukihisa Tamaki; Yoko Hieda; Rika Yoshida; Takeshi Yoshizako; Takafumi Fuchiwaki; Noriaki Aoi; Kazumasa Sekihara; Kazuhiro Kitajima; Hideyuki Kawauchi; Hajime Kitagaki; Ryohei Sasaki; Taisuke Inomata
Journal:  Nagoya J Med Sci       Date:  2015-11       Impact factor: 1.131

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.